JP Morgan Chase
NUVB icon

JP Morgan Chase’s Nuvation Bio NUVB Stock Holding History

JP Morgan Chase’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91.1K Buy
+22,500
New +$125K ﹤0.01% 5880

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase's NUVB Position: Q1 2026 in Review

JP Morgan Chase reduced its Nuvation Bio (NUVB) stake by 9.4% in Q1 2026, selling an estimated $311K and leaving 539,162 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4035.

JP Morgan Chase first reported a position in NUVB in Q2 2021 and has held it in 20 quarters since. The position peaked at $5.71M in Q4 2021. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • JP Morgan Chase held 539,162 shares of Nuvation Bio worth $2.18M as of Q1 2026.
  • JP Morgan Chase sold 55,883 Nuvation Bio shares in Q1 2026, an estimated $311K.
  • Nuvation Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4035 holding.
  • JP Morgan Chase first reported a position in Nuvation Bio in Q2 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Nuvation Bio position peaked at $5.71M in Q4 2021.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.